JP2010529040A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010529040A5 JP2010529040A5 JP2010510531A JP2010510531A JP2010529040A5 JP 2010529040 A5 JP2010529040 A5 JP 2010529040A5 JP 2010510531 A JP2010510531 A JP 2010510531A JP 2010510531 A JP2010510531 A JP 2010510531A JP 2010529040 A5 JP2010529040 A5 JP 2010529040A5
- Authority
- JP
- Japan
- Prior art keywords
- ionic
- poly
- drug
- release
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 34
- 229940079593 drug Drugs 0.000 claims 22
- 239000003814 drug Substances 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 17
- 239000011347 resin Substances 0.000 claims 16
- 229920005989 resin Polymers 0.000 claims 16
- 238000000034 method Methods 0.000 claims 13
- 230000004888 barrier function Effects 0.000 claims 11
- 238000009792 diffusion process Methods 0.000 claims 11
- 239000013543 active substance Substances 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 9
- 239000002245 particle Substances 0.000 claims 8
- 239000011159 matrix material Substances 0.000 claims 7
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 6
- 239000003456 ion exchange resin Substances 0.000 claims 6
- 229920003303 ion-exchange polymer Polymers 0.000 claims 6
- 239000007788 liquid Substances 0.000 claims 5
- -1 methoxypropyl Chemical group 0.000 claims 4
- 239000000243 solution Substances 0.000 claims 4
- 239000004793 Polystyrene Substances 0.000 claims 3
- 239000001913 cellulose Substances 0.000 claims 3
- 229920002678 cellulose Polymers 0.000 claims 3
- 235000010980 cellulose Nutrition 0.000 claims 3
- 239000000805 composite resin Substances 0.000 claims 3
- 229910017053 inorganic salt Inorganic materials 0.000 claims 3
- 229920002223 polystyrene Polymers 0.000 claims 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 239000000020 Nitrocellulose Substances 0.000 claims 1
- 229920001054 Poly(ethylene‐co‐vinyl acetate) Polymers 0.000 claims 1
- 239000004952 Polyamide Substances 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 239000004743 Polypropylene Substances 0.000 claims 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 claims 1
- 229960005261 aspartic acid Drugs 0.000 claims 1
- 230000003190 augmentative effect Effects 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 claims 1
- 239000004621 biodegradable polymer Substances 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 239000004922 lacquer Substances 0.000 claims 1
- 229960000448 lactic acid Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 229920001220 nitrocellulos Polymers 0.000 claims 1
- 230000037074 physically active Effects 0.000 claims 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 229920000141 poly(maleic anhydride) Polymers 0.000 claims 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims 1
- 229920002502 poly(methyl methacrylate-co-methacrylic acid) Polymers 0.000 claims 1
- 229920002647 polyamide Polymers 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 108010050934 polyleucine Proteins 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 239000004926 polymethyl methacrylate Substances 0.000 claims 1
- 229920001155 polypropylene Polymers 0.000 claims 1
- 229920002635 polyurethane Polymers 0.000 claims 1
- 239000004814 polyurethane Substances 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 229920000915 polyvinyl chloride Polymers 0.000 claims 1
- 239000004800 polyvinyl chloride Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000011342 resin composition Substances 0.000 claims 1
- 239000012266 salt solution Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94095607P | 2007-05-30 | 2007-05-30 | |
| PCT/US2008/065408 WO2008151071A1 (en) | 2007-05-30 | 2008-05-30 | Modifying drug release in suspensions of ionic resin systems |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010529040A JP2010529040A (ja) | 2010-08-26 |
| JP2010529040A5 true JP2010529040A5 (enExample) | 2011-07-14 |
Family
ID=40094143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010510531A Pending JP2010529040A (ja) | 2007-05-30 | 2008-05-30 | イオン性樹脂系の懸濁液における薬物放出の調節 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8313770B2 (enExample) |
| EP (1) | EP2164631A4 (enExample) |
| JP (1) | JP2010529040A (enExample) |
| CA (1) | CA2689101C (enExample) |
| MX (1) | MX2009013019A (enExample) |
| WO (1) | WO2008151071A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2018160T3 (da) | 2006-03-16 | 2012-02-06 | Tris Pharma Inc | Modificeret depotformuleringer indeholdende lægemiddel-ionbytterharpikskomplekser |
| AU2008296298B2 (en) | 2007-09-06 | 2012-12-06 | The Cola-Cola Company | Systems and methods for monitoring and controlling the dispense of a plurality of product forming ingredients |
| RU2496711C2 (ru) | 2007-09-06 | 2013-10-27 | Дзе Кока-Кола Компани | Система и способ программирования вариантов дозирования в разливочном устройстве для приготовления продуктов |
| US20100273822A1 (en) * | 2009-04-22 | 2010-10-28 | William Wayne Howard | Immediate release compositions and methods for delivering drug formulations using strong acid ion exchange resins |
| BR112012013487A2 (pt) | 2009-12-02 | 2017-10-03 | Adamas Pharmaceuticals Inc | Composições de amantadina e métodos de uso |
| US8470375B1 (en) | 2010-01-05 | 2013-06-25 | Neos Therapeutics, Lp | Method of formulating and designing liquid drug suspensions containing ion exchange resin particles |
| US20130230587A1 (en) * | 2010-11-10 | 2013-09-05 | Rubicon Research Private Limited | Sustained release compositions |
| US9339478B2 (en) * | 2011-02-04 | 2016-05-17 | Reckitt Benckiser Llc | Pharmaceutical formulation |
| US8287903B2 (en) * | 2011-02-15 | 2012-10-16 | Tris Pharma Inc | Orally effective methylphenidate extended release powder and aqueous suspension product |
| EP2508174A1 (en) * | 2011-04-06 | 2012-10-10 | Ljiljana Sovic Brkicic | Pharmaceutical composition |
| US20130004586A1 (en) * | 2011-06-24 | 2013-01-03 | Vachon David J | Biologically Efficacious Compositions, Articles of Manufacture and Processes for Producing and/or Using Same |
| EP2726066B1 (en) | 2011-06-28 | 2021-03-31 | Neos Therapeutics, LP | Dosage forms of amphetamine for oral administration |
| CA2880456A1 (en) | 2012-08-15 | 2014-02-20 | Tris Pharma, Inc. | Methylphenidate extended release chewable tablet |
| US20140122120A1 (en) * | 2012-10-30 | 2014-05-01 | Pacesetter, Inc. | Systems and methods for providing photo-based patient verification for use with implantable medical device programmers |
| CA2898408C (en) | 2013-02-28 | 2018-01-02 | Pfizer Inc. | Enhanced stability of novel liquid compositions |
| US10154971B2 (en) | 2013-06-17 | 2018-12-18 | Adamas Pharma, Llc | Methods of administering amantadine |
| WO2016001937A2 (en) * | 2014-06-30 | 2016-01-07 | Rubicon Research Private Limited | Modified release pharmaceutical preparations |
| AU2015324986A1 (en) * | 2014-10-01 | 2017-04-20 | Crop Enhancement, Inc. | Agrochemical resinates for agricultural applications |
| US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
| JP2019515045A (ja) * | 2016-05-03 | 2019-06-06 | スペクトリックス セラピューティクス， エルエルシーＳｐｅｃｔｒｉｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｌｃ | 甲状腺ホルモン又はそのアナログを提供する組成物及び方法 |
| MX2020002078A (es) | 2017-08-24 | 2020-09-21 | Adamas Pharma Llc | Composiciones de amantadina, preparaciones de estas y métodos de uso. |
| US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
| US12458592B1 (en) | 2017-09-24 | 2025-11-04 | Tris Pharma, Inc. | Extended release amphetamine tablets |
| WO2019074829A1 (en) * | 2017-10-09 | 2019-04-18 | Rhodes Pharmaceuticals L.P. | RESINATE-BASED PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEM |
| WO2019094292A1 (en) * | 2017-11-09 | 2019-05-16 | Spectrix Therapeutics, LLC | Compositions and methods of providing thyroid hormone of analogs thereof |
| AU2018388577B2 (en) | 2017-12-18 | 2024-06-06 | Tris Pharma, Inc. | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release |
| WO2019126214A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release |
| CA3085941A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK79841C (da) * | 1952-08-04 | 1955-09-12 | Behringwerke Ag | Fremgangsmåde til fremstilling af stabile γ-globulinpræparater. |
| US3173876A (en) * | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
| US3276586A (en) * | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
| US3546142A (en) * | 1967-01-19 | 1970-12-08 | Amicon Corp | Polyelectrolyte structures |
| US3541006A (en) * | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
| US3541005A (en) * | 1969-02-05 | 1970-11-17 | Amicon Corp | Continuous ultrafiltration of macromolecular solutions |
| US4285987A (en) * | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
| US4221778A (en) * | 1979-01-08 | 1980-09-09 | Pennwalt Corporation | Prolonged release pharmaceutical preparations |
| US4762709A (en) * | 1983-09-16 | 1988-08-09 | Pennwalt Corporation | Liquid prolonged release pharmaceutical formulations containing ionic constituents |
| AU565487B2 (en) * | 1983-09-16 | 1987-09-17 | Fisons Corporation | Liquid prolonged release pharmaceutical formulations containing ionic constituents |
| US4692462A (en) * | 1985-03-18 | 1987-09-08 | Menley & James Laboratories, Ltd. | Compositions and method of controlling transdermal penetration of topical and systemic agents |
| US4999189A (en) * | 1988-11-14 | 1991-03-12 | Schering Corporation | Sustained release oral suspensions |
| GB9005498D0 (en) * | 1990-03-12 | 1990-05-09 | Beecham Group Plc | Composition |
| JP3207494B2 (ja) * | 1992-04-02 | 2001-09-10 | ロート製薬株式会社 | 水性懸濁製剤 |
| SE505146C2 (sv) * | 1995-10-19 | 1997-06-30 | Biogram Ab | Partiklar för fördröjd frisättning |
| US5980945A (en) * | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US5980882A (en) * | 1997-04-16 | 1999-11-09 | Medeva Pharmaceuticals Manufacturing | Drug-resin complexes stabilized by chelating agents |
| US6613358B2 (en) * | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US7815937B2 (en) * | 1998-10-27 | 2010-10-19 | Biovail Laboratories International Srl | Quick dissolve compositions and tablets based thereon |
| EP1250937B1 (en) * | 2001-04-09 | 2009-05-13 | Rohm And Haas Company | Controlled dissolution of active ingredients |
| CA2509429A1 (en) * | 2002-11-26 | 2004-06-10 | University Of Maryland, Baltimore | Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs |
| US20050232987A1 (en) * | 2004-03-12 | 2005-10-20 | Viswanathan Srinivasan | Dosage form containing a morphine derivative and another drug |
| EP1898913A1 (en) * | 2005-06-28 | 2008-03-19 | Ucb, S.A. | Multiple active drug-resin conjugate |
| US20070092553A1 (en) * | 2005-10-21 | 2007-04-26 | Pfab Lp | Compositions and methods of making rapidly dissolving lonically masked formulations |
-
2008
- 2008-05-30 MX MX2009013019A patent/MX2009013019A/es not_active Application Discontinuation
- 2008-05-30 EP EP08769926.0A patent/EP2164631A4/en not_active Withdrawn
- 2008-05-30 WO PCT/US2008/065408 patent/WO2008151071A1/en not_active Ceased
- 2008-05-30 JP JP2010510531A patent/JP2010529040A/ja active Pending
- 2008-05-30 US US12/130,762 patent/US8313770B2/en active Active
- 2008-05-30 CA CA2689101A patent/CA2689101C/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010529040A5 (enExample) | ||
| Halder et al. | Entrapment efficiency and release characteristics of polyethyleneimine-treated or-untreated calcium alginate beads loaded with propranolol–resin complex | |
| Roy et al. | Multiparticulate formulation approach to pulsatile drug delivery: current perspectives | |
| Kurapati et al. | Recent developments in layer-by-layer technique for drug delivery applications | |
| Ichikawa et al. | Use of ion-exchange resins to prepare 100 μm-sized microcapsules with prolonged drug-release by the Wurster process | |
| Jono et al. | A review of particulate design for pharmaceutical powders and their production by spouted bed coating | |
| Bysell et al. | Microgels and microcapsules in peptide and protein drug delivery | |
| Balabushevich et al. | Loading the multilayer dextran sulfate/protamine microsized capsules with peroxidase | |
| Shi et al. | Release behavior of thin-walled microcapsules composed of polyelectrolyte multilayers | |
| Das et al. | Preparation and evaluation of zinc–pectin–chitosan composite particles for drug delivery to the colon: Role of chitosan in modifying in vitro and in vivo drug release | |
| Anand et al. | Ion-exchange resins: carrying drug delivery forward | |
| Martins et al. | Insulin-loaded alginate microspheres for oral delivery–effect of polysaccharide reinforcement on physicochemical properties and release profile | |
| Li et al. | Progress on preparation of pH/temperature‐sensitive intelligent hydrogels and applications in target transport and controlled release of drugs | |
| US8367111B2 (en) | Extended release dosage forms of propranolol hydrochloride | |
| Yang et al. | Effects of polyvinylpyrrolidone both as a binder and pore-former on the release of sparingly water-soluble topiramate from ethylcellulose coated pellets | |
| Karthikeyan et al. | Development and characterization of zein-based micro carrier system for sustained delivery of aceclofenac sodium | |
| KR20090053858A (ko) | 이온성 수-불용성 중합체에 미세매몰된 화합물을 포함하는 약학적 고체 투여 형태 | |
| Bataglioli et al. | Interplay of the assembly conditions on drug transport mechanisms in polyelectrolyte multilayer films | |
| CN102579357B (zh) | 一种磁性复合载药微球及其制备方法 | |
| Yuksel et al. | Molecularly imprinted polymers: preparation, characterisation, and application in drug delivery systems | |
| Gandhi et al. | Chronopharmaceutics: as a clinically relevant drug delivery system | |
| Nivethaa et al. | Chitosan and chitosan based nanocomposites for applications as a drug delivery carrier: A review | |
| Mustafin | Interpolymer combinations of chemically complementary grades of Eudragit copolymers: a new direction in the design of peroral solid dosage forms of drug delivery systems with controlled release | |
| He et al. | Targeted delivery and thermo/pH-controlled release of doxorubicin by novel nanocapsules | |
| Jacobs et al. | Polymer delivery systems concepts |